Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

1.

Objective response to sorafenib in advanced clear-cell sarcoma.

Mir O, Boudou-Rouquette P, Larousserie F, Babinet A, Dumaine V, Anract P, Goldwasser F.

Ann Oncol. 2012 Mar;23(3):807-9. doi: 10.1093/annonc/mds005. Epub 2012 Jan 24. No abstract available.

PMID:
22274882
[PubMed - indexed for MEDLINE]
Free Article
2.

Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.

Lekili M, Muezzinoglu T, Nese N, Temeltas G.

J Chin Med Assoc. 2010 May;73(5):262-4. doi: 10.1016/S1726-4901(10)70056-3.

PMID:
20685594
[PubMed - indexed for MEDLINE]
3.

Sorafenib is active on lung metastases from synovial sarcoma.

Basso U, Brunello A, Bertuzzi A, Santoro A.

Ann Oncol. 2009 Feb;20(2):386-7. doi: 10.1093/annonc/mdn685. No abstract available.

PMID:
19211500
[PubMed - indexed for MEDLINE]
Free Article
4.

Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.

Schütte K, Zimmermann L, Bornschein J, Csepregi A, Rühl R, Ricke J, Malfertheiner P.

Digestion. 2011;83(4):275-82. doi: 10.1159/000320377. Epub 2011 Feb 1.

PMID:
21282952
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.

Pacey S, Ratain MJ, Flaherty KT, Kaye SB, Cupit L, Rowinsky EK, Xia C, O'Dwyer PJ, Judson IR.

Invest New Drugs. 2011 Jun;29(3):481-8. doi: 10.1007/s10637-009-9367-9. Epub 2009 Dec 18.

PMID:
20016927
[PubMed - indexed for MEDLINE]
6.

Sorafenib for advanced-stage hepatocellular carcinoma.

Tomuleasa C, Cristea V, Irimie A.

Eur J Gastroenterol Hepatol. 2012 Mar;24(3):346-7. doi: 10.1097/MEG.0b013e3283501a2e. No abstract available.

PMID:
22266833
[PubMed - indexed for MEDLINE]
7.

Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.

Valcamonico F, Ferrari V, Amoroso V, Rangoni G, Simoncini E, Marpicati P, Vassalli L, Grisanti S, Marini G.

J Neurooncol. 2009 Jan;91(1):47-50. doi: 10.1007/s11060-008-9676-4. Epub 2008 Aug 19.

PMID:
18712279
[PubMed - indexed for MEDLINE]
8.

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK.

J Clin Oncol. 2009 Jul 1;27(19):3133-40. doi: 10.1200/JCO.2008.20.4495. Epub 2009 May 18.

PMID:
19451436
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?

Kim do Y, Han KH.

J Gastroenterol Hepatol. 2011 Nov;26(11):1585-6. doi: 10.1111/j.1440-1746.2011.06901.x. No abstract available.

PMID:
22011294
[PubMed - indexed for MEDLINE]
10.

Sorafenib in advanced clear-cell renal-cell carcinoma.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group.

N Engl J Med. 2007 Jan 11;356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203.

PMID:
17215530
[PubMed - indexed for MEDLINE]
Free Article
11.

Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.

Dişel U, Oztuzcu S, Beşen AA, Karadeniz C, Köse F, Sümbül AT, Sezer A, Nursal GN, Abalı H, Ozyılkan O.

Lung Cancer. 2011 Jan;71(1):109-12. doi: 10.1016/j.lungcan.2010.09.011.

PMID:
20970876
[PubMed - indexed for MEDLINE]
12.

Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.

Tomita Y.

Int J Urol. 2010 Sep;17(9):815-6. doi: 10.1111/j.1442-2042.2010.02625.x. No abstract available.

PMID:
20727052
[PubMed - indexed for MEDLINE]
13.

Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.

Aller S, Popescu A, Rao S, Morgan E, Gosiengfiao Y.

Pediatr Blood Cancer. 2012 Jan;58(1):98-100. doi: 10.1002/pbc.23032. Epub 2011 Jun 30.

PMID:
21721105
[PubMed - indexed for MEDLINE]
14.

Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.

Pinter M, Sieghart W, Reisegger M, Wrba F, Peck-Radosavljevic M.

Wien Klin Wochenschr. 2011 Jan;123(1-2):61-4. doi: 10.1007/s00508-010-1522-y. Epub 2011 Jan 19.

PMID:
21240686
[PubMed - indexed for MEDLINE]
15.

Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.

Kuzuya T, Tsuchiya K, Izumi N.

Gan To Kagaku Ryoho. 2010 Oct;37(10):1883-86. No abstract available.

PMID:
21069944
[PubMed - indexed for MEDLINE]
16.

Molecule of the month. Sorafenib.

[No authors listed]

Drug News Perspect. 2006 Mar;19(2):119. Review. No abstract available.

PMID:
16628266
[PubMed - indexed for MEDLINE]
17.

Hepatocellular carcinoma treated with sorafenib.

Han G, Zhao Y, Qi X, Fan D.

Aliment Pharmacol Ther. 2011 Dec;34(11-12):1347-8; discussion 1348. doi: 10.1111/j.1365-2036.2011.04852.x. No abstract available.

PMID:
22085376
[PubMed - indexed for MEDLINE]
18.

Selection of patients with hepatocellular carcinoma for sorafenib.

Abou-Alfa GK.

J Natl Compr Canc Netw. 2009 Apr;7(4):397-403. Review.

PMID:
19406040
[PubMed - indexed for MEDLINE]
19.

Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.

Zhu AX, Clark JW.

Oncologist. 2009 Jan;14(1):67-9. doi: 10.1634/theoncologist.2008-0281. Epub 2009 Jan 15. No abstract available.

PMID:
19147690
[PubMed - indexed for MEDLINE]
Free Article
20.

Sorafenib in hepatocellular carcinoma.

Josephs DH, Ross PJ.

Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. Review.

PMID:
20852487
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk